Last reviewed · How we verify
Bisphosphonates Combined with Vancomycin
Bisphosphonates inhibit osteoclast-mediated bone resorption while vancomycin provides antimicrobial coverage, together targeting bone infections and promoting bone healing.
Bisphosphonates inhibit osteoclast-mediated bone resorption while vancomycin provides antimicrobial coverage, together targeting bone infections and promoting bone healing. Used for Bone infections with concurrent bone loss or osteolysis, Osteomyelitis with impaired bone healing.
At a glance
| Generic name | Bisphosphonates Combined with Vancomycin |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Combination therapy (bisphosphonate + antibiotic) |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Bisphosphonates bind to hydroxyapatite in bone and inhibit osteoclast function, reducing bone resorption and promoting bone formation. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis. The combination aims to simultaneously treat bone infections (via vancomycin) while enhancing bone regeneration and reducing pathological bone loss (via bisphosphonates).
Approved indications
- Bone infections with concurrent bone loss or osteolysis
- Osteomyelitis with impaired bone healing
Common side effects
- Nephrotoxicity (vancomycin)
- Osteonecrosis of the jaw (bisphosphonate)
- Atypical fractures (bisphosphonate)
- Ototoxicity (vancomycin)
- Gastrointestinal upset (bisphosphonate)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |